Oncology · Injection
atezolizumab · 840 mg
Tecentriq is a programmed death-ligand 1 (PD-L1) blocking antibody used to treat several cancers. It helps the immune system detect and attack tumour cells. The product is supplied as a sterile concentrate for intravenous infusion. Healthcare professionals must follow local oncology protocols and monitor patients for immune-mediated adverse reactions during treatment.
Tecentriq is a fully humanised, engineered monoclonal antibody of immunoglobulin G1 (IgG1) isotype that binds to PD-L1 and inhibits its interaction with PD-1 and B7.1 receptors. This restores anti-tumour T-cell activity. It is approved in combination or as monotherapy for urothelial carcinoma and non-small cell lung cancer.
Urothelial carcinoma and non-small cell lung cancer as monotherapy or in combination with bevacizumab, paclitaxel and carboplatin.
840 mg intravenous infusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity.
Warnings include immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies and infusion-related reactions. Monitor liver and thyroid function.
Use in pregnancy only if benefit outweighs risk; not recommended during breastfeeding.
No formal drug interaction studies completed; use caution with immunosuppressive agents.
Store at 2-8°C, protect from light. Do not freeze.
This product information is provided for educational purposes only and is not a substitute for professional medical advice.
